1. Accueil >
  2. Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label >
Nasdaq

Novo Nordisk submits application in the EU for including data from the DEVOTE trial in the Tresiba® label

14-06-2017

Bagsværd, Denmark, 14 June 2017
- Novo Nordisk today announced the submission of a Type II Variation application to the European Medicines Agency (EMA) for including data in the label for Tresiba
®
(insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba
®
compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.

Further information

Media:    
Katrine Sperling +45 4442 6718 krsp@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors
: 		   
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 44/2017


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

HUG#2113155